Brain Tumour Research has announced it has become a partner of the British Association for Cancer Research (BACR).
The BACR was formed in 1960 to promote the advancement of research in relation to all aspects of cancer, both laboratory and clinical, and to encourage the exchange of information for patient benefit. One way it aims to achieve this is by connecting UK-based cancer charities and organisations to generate a single point of contact for researchers and funders.
Dr Karen Noble, our Director of Research, Policy and Innovation, said: “Brain Tumour Research is proud to collaborate with partners across the brain tumour and wider cancer community in order to get closer to our vision of finding a cure. Through these partnerships we strive to address the desperate need for more funding for research into brain tumours and support scientists who are at the forefront of the fight against this devastating disease.”
Accelerating the development of promising new therapies
This week, our Research Communications Manager Nicola Gale and Dr Joanna Cull, Research Funding Officer, attended the fifth review meeting of the Brain Tumour Research Novel Therapeutics Accelerator (BTR-NTA) – a programme which gives academic and industry research groups with a potential new therapeutic, device or idea for brain tumour treatment the opportunity to have their research robustly reviewed by academic and industry experts.
The Charity funds the BTR-NTA in partnership with the Tessa Jowell Brain Cancer Mission (TJBCM). Previous therapies which have been reviewed by the programme (previous meeting pictured top) include TGX-007, a viral immunotherapy technology to treat glioblastoma from Trogenix Ltd, an Edinburgh-based company, and ActNano, which utilises approved anti-cancer agents encapsulated in nanoparticles which can be tracked via MRI prior to activation using focused ultrasound to treat brain cancer.
The latest BTR-NTA meeting concludes today at New York University. An expert panel has reviewed four potential new treatments with the aim of helping researchers to position their therapeutic on a realistic path to clinical benefit for patients, speeding up the progress of new treatments and, ultimately, helping to improve options for brain tumour patients.
Your donations make it possible for us to support initiatives such as this which will help progress research into brain tumours in order to get us closer to a cure. Please donate what you can to help fund the fight.
Related reading:
